CDY
vs
S
S&P/ASX 300
CDY
Over the past 12 months, CDY has underperformed S&P/ASX 300, delivering a return of 0% compared to the S&P/ASX 300's +3% growth.
Stocks Performance
CDY vs S&P/ASX 300
Performance Gap
CDY vs S&P/ASX 300
Performance By Year
CDY vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Cellmid Ltd
Glance View
Cellmid Ltd. operates as a biotechnology company, which engages in the development and marketing of therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. The company is headquartered in Sydney, New South Wales. The company went IPO on 2005-12-09. The firm is specialized in developing anti-aging solutions. The firm operates through two segments: Diagnostics and Consumer Health. The firm is engaged in the research and development of diagnostic and therapeutic products for the management of diseases, such as cancer and various chronic inflammatory conditions by targeting midkine. The company is also engaged in the development and sale of over the counter (OTC) and cosmetic products for hair loss and anti-aging hair care through its FGF5 inhibitor technology. The company has developed a range of products under the evolis, evolis Professional, Lexilis Hybrid, Jo-JuRED and Lexilis BLACK brands.
